{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:13:21Z","timestamp":1772864001778,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>The aim of the present study was to evaluate the efficacy and safety of ipragliflozin in treating Japanese type\u00a02 diabetes patients with inadequate glycemic control by investigating diurnal variations of blood glucose and body composition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This was an investigator\u2010initiated, multicenter, prospective study with a 6\u2010month treatment period. The primary outcome investigated was change in hemoglobin A1c levels from baseline. Secondary outcomes included changes in fasting plasma glucose, insulin resistance, variations in 24\u2010h glucose levels detected by continuous glucose monitoring, bodyweight, body composition, waist circumference and serum lipids. Adverse events were evaluated throughout the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 98 patients completed the study. Over the 6\u2010month period, ipragliflozin\u2010treated patients showed reduction in hemoglobin A1c levels by 0.3%, fasting plasma glucose levels by 13.0\u00a0mg\/<jats:styled-content style=\"fixed-case\">dL<\/jats:styled-content>, bodyweight by 2.1\u00a0kg, body fat mass by 1.5\u00a0kg and extracellular water by 0.3\u00a0kg, as well as a decrease in systolic\/diastolic blood pressures. Significant reductions from baseline in mean amplitude of glucose excursions and standard deviation, and the reduced frequency of hyperglycemia were confirmed. High\u2010density lipoprotein cholesterol was also significantly improved. Notably, the subgroup analysis of hemoglobin A1c levels, bodyweight, waist circumference, and body composition based on age, sex and body mass index showed similar reductions within each subgroup. The incidences of adverse events and adverse drug reactions were 20.0% and 1.0%, respectively, over the 6\u2010month period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ipragliflozin is a useful oral antidiabetic medication for patients with a wide range of background characteristics.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.12705","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T21:53:42Z","timestamp":1498254822000},"page":"341-353","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of ipragliflozin as monotherapy or as add\u2010on therapy with other oral antidiabetic medications for treating type\u00a02 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics"],"prefix":"10.1111","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-9277","authenticated-orcid":false,"given":"Takeshi","family":"Osonoi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Naka Kinen Clinic Naka Ibaraki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Naka Kinen Clinic Naka Ibaraki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyoko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Naka Kinen Clinic Naka Ibaraki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Tamasawa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Naka Kinen Clinic Naka Ibaraki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Naka Kinen Clinic Naka Ibaraki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Osonoi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Naka Kinen Clinic Naka Ibaraki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01511.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S50773"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0297-x"},{"key":"e_1_2_7_6_1","first-page":"155","article-title":"Options for empagliflozin in combination therapy in type 2 diabetes mellitus","volume":"9","author":"Hershon KS","year":"2016","journal-title":"Int J Gen Med"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12156"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.07.020"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12403"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12331"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12471"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2016.1145668"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12370"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0523"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-014-0164-0"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-014-0182-y"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-014-0184-9"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.66.987"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12481"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12611"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0291-z"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2806"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01128.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12384"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01552.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2417w"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ15-0749"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.02.003"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.12705","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.12705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T22:22:52Z","timestamp":1695507772000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.12705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/jdi.12705"],"URL":"https:\/\/doi.org\/10.1111\/jdi.12705","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,13]]}}}